Literature DB >> 27063266

The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis.

Pushpjeet Kanwar1, Kris V Kowdley2.   

Abstract

Nonalcoholic steatohepatitis (NASH) and the metabolic syndrome (MetS) are highly prevalent in the Western population. Their pathogenesis is closely linked to insulin resistance, which serves as a therapeutic target for the management of these conditions. This review article reviews the research supporting the influence of MetS on NASH and includes studies supporting their similar epidemiology, pathogenesis, and treatment.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma; Metabolic syndrome; NAFLD; Nonalcoholic steatohepatitis; Risk factors

Mesh：

Substances：

Year:  2015        PMID： 27063266     DOI： 10.1016/j.cld.2015.10.002

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN： 1089-3261            Impact factor:   6.126


  27 in total

Review 1.  Role of the Circadian Clock in the Metabolic Syndrome and Nonalcoholic Fatty Liver Disease.

Authors:  Akshay Shetty; Jennifer W Hsu; Paul P Manka; Wing-Kin Syn
Journal:  Dig Dis Sci       Date:  2018-08-18       Impact factor: 3.199

2.  Active p38α causes macrovesicular fatty liver in mice.

Authors:  Ilona Darlyuk-Saadon; Chen Bai; Chew Kiat Matthew Heng; Nechama Gilad; Wei-Ping Yu; Pei Yen Lim; Amaury Cazenave-Gassiot; Yongliang Zhang; W S Fred Wong; David Engelberg
Journal:  Proc Natl Acad Sci U S A       Date:  2021-04-06       Impact factor: 11.205

Review 3.  Phytochemicals targeting NAFLD through modulating the dual function of forkhead box O1 (FOXO1) transcription factor signaling pathways.

Authors:  Usman Sabir; Hafiz Muhammad Irfan; Ihtisham Umer; Zahid Rasul Niazi; Hafiz Muhammad Mazhar Asjad
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-03-31       Impact factor: 3.000

4.  Responsiveness on metabolic syndrome criteria and hepatic parameters after 12 weeks and 24 weeks of multidisciplinary intervention in overweight adolescents.

Authors:  N Leite; M C Tadiotto; P R P Corazza; F J de Menezes Junior; M E C Carli; G E Milano-Gai; W A Lopes; A R Gaya; C Brand; J Mota; R B Radominski
Journal:  J Endocrinol Invest       Date:  2021-11-15       Impact factor: 4.256

5.  Amitriptyline inhibits nonalcoholic steatohepatitis and atherosclerosis induced by high-fat diet and LPS through modulation of sphingolipid metabolism.

Authors:  Zhongyang Lu; Yanchun Li; Wing-Kin Syn; Zhewu Wang; Maria F Lopes-Virella; Timothy J Lyons; Yan Huang
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-12-10       Impact factor: 4.310

6.  Child-Turcotte-Pugh Score, MELD Score and MELD-Na Score as Predictors of Short-Term Mortality among Patients with End-Stage Liver Disease in Northern India.

Authors:  Gagandeep Acharya; Rajeev Mohan Kaushik; Rohit Gupta; Reshma Kaushik
Journal:  Inflamm Intest Dis       Date:  2019-11-08

Review 7.  Nonalcoholic fatty liver disease and COVID-19: An epidemic that begets pandemic.

Authors:  Musaab Ahmed; Mohamed H Ahmed
Journal:  World J Clin Cases       Date:  2021-06-16       Impact factor: 1.337

8.  Telemonitoring-Supported Exercise Training in Employees With Metabolic Syndrome Improves Liver Inflammation and Fibrosis.

Authors:  Sven Haufe; Katharina L Hupa-Breier; Pauline Bayerle; Hedwig T Boeck; Simone Rolff; Thorben Sundermeier; Arno Kerling; Julian Eigendorf; Momme Kück; Alexander A Hanke; Ralf Ensslen; Lars Nachbar; Dirk Lauenstein; Dietmar Böthig; Denise Hilfiker-Kleiner; Meike Stiesch; Christoph Terkamp; Heiner Wedemeyer; Axel Haverich; Uwe Tegtbur
Journal:  Clin Transl Gastroenterol       Date:  2021-06-18       Impact factor: 4.488

9.  GPR40 deficiency is associated with hepatic FAT/CD36 upregulation, steatosis, inflammation, and cell injury in C57BL/6 mice.

Authors:  Zhongyang Lu; Yanchun Li; Wing-Kin Syn; Ai-Jun Li; W Sue Ritter; Stephen A Wank; Maria F Lopes-Virella; Yan Huang
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-10-26       Impact factor: 4.310

Review 10.  The Therapeutic Effects and Mechanisms of Quercetin on Metabolic Diseases: Pharmacological Data and Clinical Evidence.

Authors:  Huan Yi; Hengyang Peng; Xinyue Wu; Xinmei Xu; Tingting Kuang; Jing Zhang; Leilei Du; Gang Fan
Journal:  Oxid Med Cell Longev       Date:  2021-06-23       Impact factor: 6.543
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.